Cited by 462Redox biology and oxidative stressBioactive Compounds and Antitumor AgentsCancer and biochemical research

Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities

Open access
Wondrak, Georg T.·2009·Antioxidants & Redox Signaling

Abstract

Redox dysregulation originating from metabolic alterations and dependence on mitogenic and survival signaling through reactive oxygen species represents a specific vulnerability of malignant cells that can be selectively targeted by redox chemotherapeutics. This review will present an update on drug discovery, target identification, and mechanisms of action of experimental redox chemotherapeutics with a focus on pro- and antioxidant redox modulators now in advanced phases of preclinal and clinical development. Recent research indicates that numerous oncogenes and tumor suppressor genes exert their functions in part through redox mechanisms amenable to pharmacological intervention by redox chemotherapeutics. The pleiotropic action of many redox chemotherapeutics that involves simultaneous modulation of multiple redox sensitive targets can overcome cancer cell drug resistance originating from redundancy of oncogenic signaling and rapid mutation.Moreover, some redox chemotherapeutics may function according to the concept of synthetic lethality (i.e., drug cytotoxicity is confined to cancer cells that display loss of function mutations in tumor suppressor genes or upregulation of oncogene expression). The impressive number of ongoing clinical trials that examine therapeutic performance of novel redox drugs in cancer patients demonstrates that redox chemotherapy has made the crucial transition from bench to bedside.

Integrity signals

Registry

Crossref · 10.1089/ars.2009.2541

Cites

406 of 406 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Existing pro-oxidant cancer therapies frequently damage healthy tissue and have a small therapeutic window.

    “current pro-oxidant strategies often cause serious collateral damage, resulting in a narrow therapeutic window20”

    From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [20]

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wondrak, G. T.
Affiliations
University of Arizona (US)
Corresponding author
Wondrak, Georg T.
Venue
Antioxidants & Redox Signaling
Published
2009-12
Volume
11
Issue
12
Pages
3013-3069
ISSN
  • 1523-0864 (ISSN-L)
  • 1557-7716
OpenAlex
W2000718634
Cited by
462
References
406
Citations by year
2026: 7 · 2025: 24 · 2024: 16 · 2023: 18 · 2022: 18 · 2021: 23 · 2020: 25 · 2019: 29 · 2018: 26 · 2017: 35 · 2016: 44 · 2015: 42 · 2014: 40 · 2013: 33 · 2012: 34
FWCI
2.09
Type
journal article
Language
en
Open access
Locations
  • Antioxidants and Redox Signaling (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Arizona Cancer Center (CA023074)
  • Servier
  • National Institutes of Health (CA023074, ES 06694)
  • National Cancer Institute (R01CA122484, CA-023074, P30CA023074)
  • National Institute of Environmental Health Sciences (ES 06694, P30ES006694)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
Keywords
reactive oxygen species, redox dysregulation, cancer cell vulnerability, oncogene function, tumor suppressor, chemoresistance, synthetic lethality, redox signaling, drug discovery, clinical trials
MeSH terms
Antineoplastic Agents, Humans, Neoplasms, Oxidation-Reduction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review